A Prospective Cohort Study in Nonhospitalized Household Contacts With Severe Acute Respiratory Syndrome Coronavirus 2 Infection: Symptom Profiles and Symptom Change Over Time.


Journal

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
ISSN: 1537-6591
Titre abrégé: Clin Infect Dis
Pays: United States
ID NLM: 9203213

Informations de publication

Date de publication:
05 10 2021
Historique:
received: 30 06 2020
accepted: 23 07 2020
pubmed: 29 7 2020
medline: 16 10 2021
entrez: 29 7 2020
Statut: ppublish

Résumé

Improved understanding of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spectrum of disease is essential for clinical and public health interventions. There are limited data on mild or asymptomatic infections, but recognition of these individuals is key as they contribute to viral transmission. We describe the symptom profiles from individuals with mild or asymptomatic SARS-CoV-2 infection. From 22 March to 22 April 2020 in Wisconsin and Utah, we enrolled and prospectively observed 198 household contacts exposed to SARS-CoV-2. We collected and tested nasopharyngeal specimens by real-time reverse-transcription polymerase chain reaction (rRT-PCR) 2 or more times during a 14-day period. Contacts completed daily symptom diaries. We characterized symptom profiles on the date of first positive rRT-PCR test and described progression of symptoms over time. We identified 47 contacts, median age 24 (3-75) years, with detectable SARS-CoV-2 by rRT-PCR. The most commonly reported symptoms on the day of first positive rRT-PCR test were upper respiratory (n = 32 [68%]) and neurologic (n = 30 [64%]); fever was not commonly reported (n = 9 [19%]). Eight (17%) individuals were asymptomatic at the date of first positive rRT-PCR collection; 2 (4%) had preceding symptoms that resolved and 6 (13%) subsequently developed symptoms. Children less frequently reported lower respiratory symptoms (21%, 60%, and 69% for <18, 18-49, and ≥50 years of age, respectively; P = .03). Household contacts with laboratory-confirmed SARS-CoV-2 infection reported mild symptoms. When assessed at a single timepoint, several contacts appeared to have asymptomatic infection; however, over time all developed symptoms. These findings are important to inform infection control, contact tracing, and community mitigation strategies.

Sections du résumé

BACKGROUND
Improved understanding of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spectrum of disease is essential for clinical and public health interventions. There are limited data on mild or asymptomatic infections, but recognition of these individuals is key as they contribute to viral transmission. We describe the symptom profiles from individuals with mild or asymptomatic SARS-CoV-2 infection.
METHODS
From 22 March to 22 April 2020 in Wisconsin and Utah, we enrolled and prospectively observed 198 household contacts exposed to SARS-CoV-2. We collected and tested nasopharyngeal specimens by real-time reverse-transcription polymerase chain reaction (rRT-PCR) 2 or more times during a 14-day period. Contacts completed daily symptom diaries. We characterized symptom profiles on the date of first positive rRT-PCR test and described progression of symptoms over time.
RESULTS
We identified 47 contacts, median age 24 (3-75) years, with detectable SARS-CoV-2 by rRT-PCR. The most commonly reported symptoms on the day of first positive rRT-PCR test were upper respiratory (n = 32 [68%]) and neurologic (n = 30 [64%]); fever was not commonly reported (n = 9 [19%]). Eight (17%) individuals were asymptomatic at the date of first positive rRT-PCR collection; 2 (4%) had preceding symptoms that resolved and 6 (13%) subsequently developed symptoms. Children less frequently reported lower respiratory symptoms (21%, 60%, and 69% for <18, 18-49, and ≥50 years of age, respectively; P = .03).
CONCLUSIONS
Household contacts with laboratory-confirmed SARS-CoV-2 infection reported mild symptoms. When assessed at a single timepoint, several contacts appeared to have asymptomatic infection; however, over time all developed symptoms. These findings are important to inform infection control, contact tracing, and community mitigation strategies.

Identifiants

pubmed: 32719874
pii: 5877084
doi: 10.1093/cid/ciaa1072
pmc: PMC7454397
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e1841-e1849

Subventions

Organisme : CDC SARS-CoV-2

Informations de copyright

Published by Oxford University Press for the Infectious Diseases Society of America 2020.

Auteurs

Anna R Yousaf (AR)

COVID-19 Response Team, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
Epidemic Intelligence Service, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.

Lindsey M Duca (LM)

COVID-19 Response Team, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
Epidemic Intelligence Service, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.

Victoria Chu (V)

COVID-19 Response Team, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
Epidemic Intelligence Service, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.

Hannah E Reses (HE)

COVID-19 Response Team, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.

Mark Fajans (M)

COVID-19 Response Team, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.

Elizabeth M Rabold (EM)

COVID-19 Response Team, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
Epidemic Intelligence Service, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.

Rebecca L Laws (RL)

COVID-19 Response Team, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.

Radhika Gharpure (R)

COVID-19 Response Team, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
Epidemic Intelligence Service, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.

Almea Matanock (A)

COVID-19 Response Team, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.

Ashutosh Wadhwa (A)

COVID-19 Response Team, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
Laboratory Leadership Service, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.

Mary Pomeroy (M)

COVID-19 Response Team, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
Epidemic Intelligence Service, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.

Henry Njuguna (H)

COVID-19 Response Team, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.

Garrett Fox (G)

COVID-19 Response Team, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.

Alison M Binder (AM)

COVID-19 Response Team, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.

Ann Christiansen (A)

North Shore Health Department, Milwaukee, Wisconsin, USA.

Brandi Freeman (B)

COVID-19 Response Team, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
Laboratory Leadership Service, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.

Christopher Gregory (C)

COVID-19 Response Team, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.

Cuc H Tran (CH)

COVID-19 Response Team, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.

Daniel Owusu (D)

COVID-19 Response Team, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
Epidemic Intelligence Service, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.

Dongni Ye (D)

COVID-19 Response Team, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.

Elizabeth Dietrich (E)

COVID-19 Response Team, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.

Eric Pevzner (E)

COVID-19 Response Team, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.

Erin E Conners (EE)

COVID-19 Response Team, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.

Ian Pray (I)

COVID-19 Response Team, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
Epidemic Intelligence Service, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
Wisconsin Department of Health, Milwaukee, Wisconsin, USA.

Jared Rispens (J)

COVID-19 Response Team, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
Epidemic Intelligence Service, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.

Jeni Vuong (J)

COVID-19 Response Team, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.

Kim Christensen (K)

Utah Department of Health, Salt Lake City, Utah, USA.

Michelle Banks (M)

COVID-19 Response Team, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.

Michelle O'Hegarty (M)

COVID-19 Response Team, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.

Lisa Mills (L)

COVID-19 Response Team, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.

Sandra Lester (S)

COVID-19 Response Team, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.

Natalie J Thornburg (NJ)

COVID-19 Response Team, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.

Nathaniel Lewis (N)

COVID-19 Response Team, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
Epidemic Intelligence Service, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
Utah Department of Health, Salt Lake City, Utah, USA.

Patrick Dawson (P)

COVID-19 Response Team, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
Epidemic Intelligence Service, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.

Perrine Marcenac (P)

COVID-19 Response Team, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
Epidemic Intelligence Service, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.

Phillip Salvatore (P)

COVID-19 Response Team, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
Epidemic Intelligence Service, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.

Rebecca J Chancey (RJ)

COVID-19 Response Team, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.

Victoria Fields (V)

COVID-19 Response Team, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
Epidemic Intelligence Service, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.

Sean Buono (S)

COVID-19 Response Team, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
Laboratory Leadership Service, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.

Sherry Yin (S)

COVID-19 Response Team, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.

Susan Gerber (S)

COVID-19 Response Team, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.

Tair Kiphibane (T)

Salt Lake County Health Department, Salt Lake City, Utah, USA.

Trivikram Dasu (T)

City of Milwaukee Health Department, Milwaukee, Wisconsin, USA.

Sanjib Bhattacharyya (S)

City of Milwaukee Health Department, Milwaukee, Wisconsin, USA.

Ryan Westergaard (R)

North Shore Health Department, Milwaukee, Wisconsin, USA.

Angela Dunn (A)

Laboratory Leadership Service, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.

Aron J Hall (AJ)

COVID-19 Response Team, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.

Alicia M Fry (AM)

COVID-19 Response Team, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.

Jacqueline E Tate (JE)

COVID-19 Response Team, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.

Hannah L Kirking (HL)

COVID-19 Response Team, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.

Scott Nabity (S)

COVID-19 Response Team, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH